Short answer
ResMed (RMD) filed its Q4 2025 10-Q quarterly report on Jan 30, 2026 for the quarter ended Dec 31, 2025. Quarterly revenue was $1.4B (up 11.0% year over year) with net income of $393M.
Q4 2025 key financials · XBRL
- Revenue
- $1.4B
- +11.0% YoY · +6.5% QoQ
- Net income
- $393M
- +13.9% YoY · +12.6% QoQ
- Operating margin
- 34.6%
- Gross margin
- 61.8%
- EPS (diluted)
- $2.68
- +14.5% YoY · +13.1% QoQ
Source: XBRL data from the ResMed (RMD) Q4 2025 10-Q on SEC EDGAR. USD.
ResMed Q4 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $1.423B for Q2 FY2025, up 11% YoY from $1.282B in Q2 FY2024; Sleep and Breathing Health segment up 12%, Residential Care Software up 7%
- Gross margin 61.8% in Q2 FY2025 vs 58.6% YoY; operating expenses increased, SG&A 19.6% of revenue vs 18.8% YoY, R&D at 6.4% vs 6.3%
- Best performing: Masks and other products revenue up 16% to $529.7M; worst performing: Residential Care Software with slower 7% growth
- Cash and cash equivalents rose to $1.417B at Dec 31, 2025 from $1.209B at June 30, 2025; operating cash flow $797.1M for six months up $162.9M YoY; treasury stock repurchases $325M
- Management cites continued growth driven by new product AirSense 11, expects ongoing innovation; notes global minimum tax impact on income tax rate increase to 20.9% for quarter; expects sufficient liquidity for next 12 months
Risk Factors
- No new or changed risk factors since 10-K for fiscal year ended June 30, 2025
- Continued exposure to product liability risks from medical device use as previously disclosed
- Ongoing compliance risk with evolving global healthcare regulations, including FDA and EU MDR standards
- Market risk from competitive pressure in sleep apnea device segment impacting near-term sales growth
- Foreign currency exchange fluctuations affecting revenue as approximately 40% of sales are international
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ResMed quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.